AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26911887
Drug: Standard low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard low-dose protocol
Trial: 18589019
Drug: Mediterranean diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean diet with free virgin olive oil (1 L/week)
Trial: 18589019
Drug: Mediterranean diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean diet with free mixed nuts (30 g/day)
Trial: 18589019
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (verbal instructions and leaflet recommending National Cholesterol Education Program Adult Treatment Panel III dietary guidelines)
Trial: 15802772
Drug: Vitamin K2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K2 (menatetrenone, MK‐4) 45 mg/day
Trial: 12575213
Drug: Sparfloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin (200 mg once daily intravenous drip)
Trial: 31912800
Drug: Istiratumab (2.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Istiratumab (2.8 g intravenously every 2 weeks)
Trial: 30894210
Drug: HF-LED-RL phototherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HF-LED-RL phototherapy at doses of 480 J/cm2 and 640 J/cm2
Trial: 27484782
Drug: Mock therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mock therapy
Trial: 22094316
Drug: Rapid rehydration
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid rehydration (60 mL/kg) with 0.9% saline over an hour
Trial: 19015353
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of ritonavir
Trial: 19015353
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of elvucitabine coadministered with 300 mg of ritonavir
Trial: 9413102
Drug: Td +
RxNorm normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Td + full strength acellular pertussis vaccine (PT, 1 microgram/0.5 ml; FHA, 4 micrograms/0.5 ml)
Trial: 9413102
Drug: Td +
RxNorm normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Td + half strength acellular pertussis vaccine
Trial: 8480701
Drug: rhGH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH therapy (experimental group, n = 18)
Trial: 31109255
Drug: Referral for
RxNorm normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral for treatment
Trial: 31109255
Drug: Reasons for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reasons for seeking treatment
Trial: 23868016
Drug: Barriers to
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barriers to treatment
Trial: 31666270
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous paracetamol (15 mg/kg initially, followed by 7.5 mg/kg every 6 hours for 5 days)
Trial: 19798634
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release acipimox capsules
Trial: 16820995
Drug: Ambroxol (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol (45 mg/day)
Trial: 16820995
Drug: Carbocisteine (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbocisteine (1500 mg/day)
Trial: 20924615
Drug: Rebamipide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebamipide (300 mg/day)
Trial: 10853205
Drug: Manual lung
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual lung hyperinflation treatment (patient positioning, suctioning, and manual lung hyperinflation)
Trial: 10853205
Drug: Manual lung
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual lung hyperinflation treatment
Trial: 10853205
Drug: Side-lying treatment
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Side-lying treatment (patient positioning and suctioning)
Trial: 8096526
Drug: Gepirone 2
RxNorm normalized name: gepirone 18.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepirone 2 mg/day increasing to 12 mg/day over 3 weeks
Trial: 2427836
Drug: Celiprolol 200
RxNorm normalized name: celiprolol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol 200 mg
Trial: 2427836
Drug: Celiprolol 400
RxNorm normalized name: celiprolol 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol 400 mg
Trial: 29717839
Drug: Oral Testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Testosterone Undecanoate Capsules (TUC) combined with Qilin Pills (QLP) (6g, tid) for 3 months
Trial: 29717839
Drug: Oral Testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Testosterone Undecanoate Capsules (TUC) (80 mg, qd) for 3 months
Trial: 25788231
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (including balloon aortic valvuloplasty)
Trial: 23733499
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy (10 W class IV laser, 6.6 ± 1.3 J/cm²)
Trial: 15325921
Drug: Alteplase and
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alteplase and lanoteplase (thrombolytic therapy)
Trial: 11230478
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy plus radiotherapy (CT/RT group)
Trial: 4581080
Drug: Slow Sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow Sodium (sodium chloride preparation)
Trial: 16523265
Drug: Sham point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham point treatment
Trial: 8930778
Drug: Clemastine solution
RxNorm normalized name: clemastine Oral Solution
DrugBank: Clemastine (DB00283)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clemastine solution (1, 2, and 4 mg)
Trial: 8930778
Drug: Clemastine tablets
RxNorm normalized name: clemastine Oral Tablet
DrugBank: Clemastine (DB00283)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clemastine tablets (1 mg and 2 mg)
Trial: 8930778
Drug: Combination tablets
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablets (1 mg or 2 mg clemastine + 75 mg phenylpropanolamine)
Trial: 10789958
Drug: Octreotide 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 0.3 mg daily (n = 9)
Trial: 10789958
Drug: Hyoscine butylbromide
RxNorm normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine butylbromide (HB) 60 mg daily (n = 9)
Trial: 1524042
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (Induction chemotherapy followed by radiotherapy)
Trial: 3542496
Drug: Colchicine therapy
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine therapy and Placebo
Trial: 19117959
Drug: 30 U/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 U/kg unfractionated heparin bolus
Trial: 19117959
Drug: 0 U/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 U/kg unfractionated heparin bolus
Trial: 19117959
Drug: 80 U/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 U/kg unfractionated heparin bolus
Trial: 12858654
Drug: RAM (ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAM (ranitidine + amoxicillin + metronidazole)
Trial: 10216104
Drug: Leukocytosis over
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukocytosis over 100 +/- 10(9)/L
Trial: 31293259
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral feeding
Trial: 2613390
Drug: Vadocaine hydrochloride
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vadocaine hydrochloride tablet (30 mg t.i.d. for four days)
Trial: 2613390
Drug: Vadocaine hydrochloride
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vadocaine hydrochloride solution
Trial: 796755
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg chlorpromazine‐‐500 mg alpha‐methyldopa/day
Trial: 796755
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg chlorpromazine‐‐750 mg alpha‐methyldopa/day
Trial: 20391510
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (100 mg every other day)
Trial: 16716319
Drug: Laser-assisted intracytoplasmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser-assisted intracytoplasmic sperm injection (ICSI)
Trial: 12920491
Drug: Quinine hydrochloride
RxNorm normalized name: quinine hydrochloride
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinine hydrochloride (500 mg) alone
Trial: 10867536
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg folic acid daily for 3 months
Trial: 6347746
Drug: Nimesulide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide (200 mg/day)
Trial: 30376860
Drug: Intravenous artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous artesunate
Trial: 1287905
Drug: Intramuscular artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intramuscular artesunate
Trial: 29570108
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg/kg intravenous lidocaine over 5 min followed by 2 mg/kg/h)
Trial: 26821712
Drug: Religiously-tailored HIV
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Religiously-tailored HIV education and testing materials/activities delivered by church leaders (e.g., sermons, brochures/bulletins, testimonials)
Trial: 22958024
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (3.5 g kg(‐1) per day)
Trial: 15693916
Drug: mMMDT 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mMMDT 80 mg/kg/day
Trial: 15693916
Drug: mMMDT 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mMMDT 40 mg/kg/day
Trial: 2122007
Drug: Neoadjuvant methotrexate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant methotrexate, cisplatin and vinblastine chemotherapy plus 2 additional courses of cisplatin and 4,000 cGy irradiation.
Trial: 2122007
Drug: Full chemotherapy
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full chemotherapy and radiotherapy (including a radiotherapy boost to a total of 6,480 cGy plus 1 additional course of cisplatin).
Trial: 2122007
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with dose reductions due to stomatitis, bone marrow depression, and/or renal dysfunction.
Trial: 2122007
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment efficacy and tolerability.
Trial: 31563397
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg dexamethasone IV 24 hours after surgery
Trial: 10753434
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline injection (control group)
Trial: 30206195
Drug: ACT-based stress
RxNorm normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-based stress management program (twice a week for four weeks)
Trial: 24030238
Drug: Multicomponent exercise
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent exercise program (twice-weekly for 12 weeks, including muscle power training at 40-60% of one-repetition maximum, balance and gait retraining)
Trial: 22565589
Drug: Weight based,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight based, higher-dose (HD) enoxaparin 0.5 mg/kg QDay, n = 11
Trial: 22565589
Drug: Weight based,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight based, lower-dose (LD) enoxaparin 0.4 mg/kg QDay, n = 9
Trial: 22565589
Drug: Fixed-dose (FD)
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose (FD) enoxaparin 40 mg daily, n = 11
Trial: 11882226
Drug: Prilocaine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prilocaine (3 mg/kg)
Trial: 11882226
Drug: Lidocaine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (3 mg/kg)
Trial: 9496204
Drug: Propofol-low-dose fentanyl-nitrous
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol-low-dose fentanyl-nitrous oxide-vecuronium, tracheal extubation immediately after surgery (group Ia)
Trial: 10862645
Drug: Triple-drug therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-drug therapy without change (Group B)
Trial: 8418174
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for Chlamydia-positive NGU
Trial: 8418174
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for gonorrhea
Trial: 8418174
Drug: Chlamydia-positive NGU
RxNorm normalized name: Chlamydia trachomatis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlamydia-positive NGU after cessation of therapy
Trial: 25641591
Drug: Stretch-and-flow voice
RxNorm normalized name: Mederma Stretch Mark Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stretch-and-flow voice therapy
Trial: 19454032
Drug: Dexmedetomidine 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.2 to 0.7 microg/kg/hr (with or without loading doses of 1 microg/kg)
Trial: 16736128
Drug: Glucose concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose concentrations of 8.3 mmol/l
Trial: 16736128
Drug: Glucose concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose concentrations of 11.1 mmol/l
Trial: 16736128
Drug: Co-infusion of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-infusion of insulin
Trial: 10228257
Drug: Somatostatin infusion
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin infusion
Trial: 15001601
Drug: Fluvastatin XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin XL (80 mg), once-daily for 8 weeks
Trial: 15001601
Drug: Placebo, once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, once-daily for 8 weeks
Trial: 3101484
Drug: Ten-day penicillin
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ten-day penicillin V potassium therapy (250 mg three times daily)
Trial: 18091007
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of print materials and pedometer (COM)
Trial: 29935939
Drug: Acute ∆9‐THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute ∆9‐THC administration
Trial: 26909743
Drug: Curcuminoids (294
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoids (294 mg per day as micelles)
Trial: 23379240
Drug: Afala, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afala, 2 tablets 4 times a day for 6 months
Trial: 18359717
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of nebulized budesonide suspension plus salbutamol and ipratropium bromide twice daily for 5 days (Group A)
Trial: 18359717
Drug: Dexamethasone plus
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone plus aminophylline injection once daily for 5 days (Group C)
Trial: 9528844
Drug: Ifosfamide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide (3 g m(‐2) x (2 or 3) days as a 1‐h bolus)
Trial: 9528844
Drug: Ifosfamide (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide (same total dose as continuous infusion)
Trial: 2650643
Drug: Topical antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antimicrobial therapy and skin grafting after spontaneous eschar separation
Trial: 2650643
Drug: Early excision
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early excision and topical antimicrobial therapy
Trial: 1159265
Drug: Diazepam (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (12 mg daily for two weeks)
Trial: 24861133
Drug: Ticagrelor (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (180 mg single oral dose) plus Cyclosporine (600 mg single oral dose)
Trial: 22648712
Drug: [¹³C]Palmitate and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [¹³C]Palmitate and octanoate administered via gastrointestinal endoscopy
Trial: 18221433
Drug: Oral controlled-release
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral controlled-release alpha-lipoic acid (CRLA) for 3 months
Trial: 16318978
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg dydrogesterone per day during the first trimester of pregnancy
Trial: 9322808
Drug: Lovastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (40 mg/d)
Trial: 29656442
Drug: Lenvatinib (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib (24 mg/d on a 28-day cycle)
Trial: 26756115
Drug: Insulin during
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin during euglycemic hyperinsulinemia
Trial: 26756115
Drug: Baseline and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline and post-insulin clamp
Trial: 15828852
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg famotidine (single dose, intravenous or oral)
Trial: 15828852
Drug: 0.25 mg/kg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg/dose intravenously or 0.5 mg/kg/dose orally (multiple doses)
Trial: 15828852
Drug: 0.5 mg/kg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg/dose intravenously or 1 mg/kg/dose orally (subsequent doses)
Trial: 8625185
Drug: Pelvic intraarterial
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic intraarterial chemotherapy (IAC) with mitomycin-C (10 mg/m2), vincristine (1 mg/m2), and cisplatin (50 mg/m2)
Trial: 8625185
Drug: Pelvic intraarterial
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic intraarterial chemotherapy (IAC) with mitomycin-C (10 mg/m2), vincristine (1 mg/m2), and cisplatin (75 mg/m2)
Trial: 8625185
Drug: Pelvic intraarterial
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic intraarterial chemotherapy (IAC) with cisplatin (75 mg/m2)
Trial: 8625185
Drug: Pelvic intraarterial
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic intraarterial chemotherapy (IAC)
Trial: 1852090
Drug: Milrinone (24-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (24-hour infusion)
Trial: 6154200
Drug: Clonidine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.1 or 0.2 mg)
Trial: 22945718
Drug: Laser +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser + Prompt L‐Pop
Trial: 19058684
Drug: Prompt L‐Pop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt L‐Pop
Trial: 22945718
Drug: Air abrasion
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air abrasion + Prompt L‐Pop
Trial: 19576277
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium nitrite (0.12 mmol NaNO(2)/mmol Hb)
Trial: 19576277
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium nitrite (0.06 mmol NaNO(2)/mmol Hb)
Trial: 19576277
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium nitrite (0.12 mmol NaNO(2)/mmol Hb)